Evidence map›Paper›PMID 38470068›Full record

GuidelineEuropean journal of neurology2024

European Academy of Neurology (EAN) guideline on the management of amyotrophic lateral sclerosis in collaboration with European Reference Network for Neuromuscular Diseases (ERN EURO-NMD).

Philip Van Damme, Ammar Al-Chalabi, Peter M Andersen, Adriano Chiò, Philippe Couratier, Mamede De Carvalho, Orla Hardiman, Magdalena Kuźma-Kozakiewicz, Albert Ludolph, Christopher J McDermott and 10 more

Abstract readPractice Guideline
PubMed Full text at PMC Publisher
In one paragraph

Guideline in European journal of neurology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 73 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
73citing papers in PubMed, 6 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

73 citing papers in PubMed, 6 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Guideline
  6. Pooled it
  7. Trial
  8. Trial
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

13 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Philip Van DammeDepartment of Neurology, University Hospitals Leuven, Department of Neuroscience KU Leuven, Center for Brain & Disease Research VIB, Leuven, Belgium.ORCID 0000-0002-4010-2357
Ammar Al-ChalabiDepartment of Basic and Clinical Neuroscience, Maurice Wohl Clinical Neuroscience Institute, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.ORCID 0000-0002-4924-7712
Peter M AndersenDepartment of Clinical Science, Neurosciences, Umeå University, Umeå, Sweden.
Adriano ChiòRita Levi Montalcini Department of Neuroscience, University of Turin, Turin, Italy.ORCID 0000-0001-9579-5341
Philippe CouratierCentre SLA, CHU Limoges, Limoges, France.ORCID 0000-0001-9562-856X
Mamede De CarvalhoFaculdade de Medicina, Instituto de Medicina Molecular, Universidade de Lisboa, Centro Académico de Medicina de Lisboa, Lisbon, Portugal.ORCID 0000-0001-7556-0158
Orla HardimanAcademic Unit of Neurology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, Ireland.ORCID 0000-0003-2610-1291
Magdalena Kuźma-KozakiewiczDepartment of Neurology, Medical University of Warsaw, Warsaw, Poland.ORCID 0000-0002-9676-1263
Albert LudolphDepartment of Neurology, Ulm University, German Center for Neurodegenerative Diseases (DZNE), Ulm, Germany.
Christopher J McDermottSheffield Institute for Translational Neuroscience, University of Sheffield, Sheffield, UK.ORCID 0000-0002-1269-9053
Jesus S MoraALS Unit, Department of Neurology, Hospital Universitario San Rafael, Madrid, Spain.
Susanne PetriDepartment of Neurology, Hannover Medical School, Hannover, Germany.ORCID 0000-0002-9783-8584
Katrin ProbynCochrane Response, London, UK.
Evy ReviersEUpALS (European Organization for Professionals and Patients with ALS) and ALS Liga België, Leuven, Belgium.
François SalachasNeurology Department, Paris ALS Center, Groupe Hospitalier Pitié-Salpêtrière, AP-HP, Paris, France.
Vincenzo SilaniDepartment of Neuroscience and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Milan, Italy.ORCID 0000-0002-7698-3854
Ole-Bjørn TysnesDepartment of Neurology, Haukeland University Hospital, Bergen, Norway.
Leonard H van den BergDepartment of Neurology, UMC Utrecht Brain Center, University Medical Center Utrecht, Utrecht, The Netherlands.ORCID 0000-0002-6559-3965
Gemma VillanuevaCochrane Response, London, UK.ORCID 0000-0002-1306-1721
Markus WeberNeuromuscular Diseases Unit/ALS Clinic, St. Gallen, Switzerland.ORCID 0000-0002-5538-9274

Funding

ALS Liga BelgiumENCALSERN Euro-NMDEUpALSEuropean Academy of Neurology
6 · The paper itself

Abstract

backgroundThis update of the guideline on the management of amyotrophic lateral sclerosis (ALS) was commissioned by the European Academy of Neurology (EAN) and prepared in collaboration with the European Reference Network for Neuromuscular Diseases (ERN EURO-NMD) and the support of the European Network for the Cure ALS (ENCALS) and the European Organization for Professionals and Patients with ALS (EUpALS).

methodsGrading of Recommendations Assessment, Development, and Evaluation (GRADE) methodology was used to assess the effectiveness of interventions for ALS. Two systematic reviewers from Cochrane Response supported the guideline panel. The working group identified a total of 26 research questions, performed systematic reviews, assessed the quality of the available evidence, and made specific recommendations. Expert consensus statements were provided where insufficient evidence was available.

resultsA guideline mapping effort revealed only one other ALS guideline that used GRADE methodology (a National Institute for Health and Care Excellence [NICE] guideline). The available evidence was scarce for many research questions. Of the 26 research questions evaluated, the NICE recommendations could be adapted for 8 questions. Other recommendations required updates of existing systematic reviews or de novo reviews. Recommendations were made on currently available disease-modifying treatments, multidisciplinary care, nutritional and respiratory support, communication aids, psychological support, treatments for common ALS symptoms (e.g., muscle cramps, spasticity, pseudobulbar affect, thick mucus, sialorrhea, pain), and end-of-life management.

conclusionsThis update of the guideline using GRADE methodology provides a framework for the management of ALS. The treatment landscape is changing rapidly, and further updates will be prepared when additional evidence becomes available.

Indexed as

Amyotrophic Lateral SclerosisEuropeHumansNeurologyNeuromuscular Diseasesdisease‐modifying treatmentgastrostomyguidelinemultidisciplinary carenon‐invasive ventilation

Identifiers

PMID38470068
PMCPMC11235832

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.